Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors

被引:31
作者
Omar M.A. [1 ]
El-Kafoury A.A. [1 ]
El-Araby R.I. [1 ]
机构
[1] El-Chatby University Children's Hospital, Department of Paediatrics, Alexandria University
关键词
Injection Site; HbA1c Level; Human Insulin; Glargine Insulin; Continuous Glucose Monitoring;
D O I
10.1186/1756-0500-4-290
中图分类号
学科分类号
摘要
Background: Despite the important implications of lipohypertrophy for diabetes control, there is a dearth of information and research about the subject in children. The aim of this study was to study the prevalence of lipohypertrophy in children with type 1 diabetes, and to evaluate the associated factors. Findings. 119 children coming for regular follow up in the diabetes clinic were examined for the presence of lipohypertrophy by inspection and palpation. The last 4 readings of glycated hemoglobin (HbA1c) levels and other factors that may affect lipohypertrophy were documented. RESULTS: The patient's age ranged from 2 months to 21 years with a median of 10 years (inter-quartile range = 6). Lipohypertrophy occurred in 54.9% of patients, more commonly in males (62.7%) vs. females (48.4%) (P = 0.074). Grade 1 lipohypertrophy occurred in 42.5% and grade 2 in 12.4%. Lipohypertrophy was related significantly to the dose of insulin units per kg of body weight (Odds ratio [OR] = 16.4; 95% CI, 2.2 - 124.6; P = 0.007), the duration of diabetes, [OR] = 1.16; 95% CI, 1.05 - 1.32; P = 0.004)), and the body mass index (BMI) [OR] = 1.68; 95% CI, 1.25 - 2.15; P = 0.006). The mean HbA1c levels of patients with grade 1 and grade 2 lipohypertrophy did not differ from diabetics without lipohypertrophy (F = 0.178, P = 0.837). Conclusions: The presence of lipohypertrophy was significantly associated with the duration of diabetes and the body mass index. Children with lipohypertrophy needed a significantly higher dose of insulin units/kg of body weight to achieve fair control compared to children without lipohypertrophy. Further studies are needed to ascertain the clinical meaning of these findings. © 2011 Omar et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 9 条
[1]  
Hauner H., Stockamp B., Haastert B., Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors, Experimental and Clinical Endocrinology and Diabetes, 104, 2, pp. 106-110, (1996)
[2]  
Kordonouri O., Lauterborn R., Deiss D., Lipohypertrophy in young patients with type 1 diabetes, Diabetes Care, 25, 3, (2002)
[3]  
Fujikura J., Fujimoto M., Yasue S., Noguchi M., Masuzaki H., Hosoda K., Tachibana T., Sugihara H., Nakao K., Insulin-induced lipohypertrophy: Report of a case with histopathology, Endocrine Journal, 52, 5, pp. 623-628, (2005)
[4]  
Hambridge K., The management of lipohypertrophy in diabetes care, Br J Nurs, 16, 9, pp. 520-4, (2007)
[5]  
Roper N.A., Bilous R.W., Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalogρ), Diabetic Medicine, 15, 12, pp. 1063-1064, (1998)
[6]  
Chowdhury T.A., Escudier V., Lesson of the week: Poor glycaemic control caused by insulin induced lipohypertrophy, British Medical Journal, 327, 7411, pp. 383-384, (2003)
[7]  
Raile K., Noelle V., Landgraf R., Schwarz H.P., Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes, Experimental and Clinical Endocrinology and Diabetes, 109, 8, pp. 393-396, (2001)
[8]  
Overland J., Molyneaux L., Tewari S., Fatouros R., Melville P., Foote D., Wu T., Yue D.K., Lipohypertrophy: Does it matter in daily life? A study using a continuous glucose monitoring system, Diabetes Obes Metab, 11, 5, pp. 460-3, (2009)
[9]  
Conwell L.S., Pope E., Artiles A.M., Mohanta A., Daneman A., Daneman D., Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents, J Pediatr, 152, 5, pp. 622-8, (2008)